Track market-moving stories before they get noisy

BlackRock Inc. purchased a new stake in shares of Hercules Capital, Inc. (NYSE:HTGC – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 924,105 shares of the financial services provider’s stock, valued at approximately $14,573,000. BlackRock Inc. owned approximately 0.49% of Hercules Capital at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of HTGC. Fox Run Management L.L.C. increased its position in Hercules Capital by 2.8% in the fourth quarter. Fox Run Management L.L.C. now owns 24,354 shares of the financial services provider’s stock worth $458,000 after purchasing an additional 657 shares during the last quarter. Centaurus Financial Inc. raised its position in shares of Hercules Capital by 1.8% during the 3rd quarter. Centaurus Financial Inc. now owns 37,819 shares of the financial services provider’s stock valued at $715,000 after buying an additional 675 shares in the last quarter. Mariner LLC raised its position in shares of Hercules Capital by 1.4% during the 4th quarter. Mariner LLC now owns 56,453 shares of the financial services provider’s stock valued at $1,062,000 after buying an additional 764 shares in the last quarter. Baker Avenue Asset Management LP lifted its holdings in shares of Hercules Capital by 8.0% in the 4th quarter. Baker Avenue Asset Management LP now owns 11,896 shares of the financial services provider’s stock valued at $224,000 after acquiring an additional 881 shares during the last quarter. Finally, Integrated Wealth Concepts LLC grew its position in Hercules Capital by 5.9% in the first quarter. Integrated Wealth Concepts LLC now owns 17,241 shares of the financial services provider’s stock worth $331,000 after acquiring an additional 959 shares in the last quarter. 19.69% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In A number of brokerages have issued reports on HTGC. Weiss Ratings restated a “hold (c)” rating on shares of Hercules Capital in a research report on Wednesday, June 17th. UBS Group upgraded Hercules Capital from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $15.50 to $18.50 in a report on Tuesday. Finally, LADENBURG THALM/SH SH decreased their price target on Hercules Capital from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Hercules Capital presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.89.

Get Our Latest Stock Report on Hercules Capital Hercules Capital Trading Up 0.1% HTGC opened at $17.72 on Friday. The stock’s fifty day moving average is $16.54 and its two-hundred day moving average is $15.69. The company has a market capitalization of $3.32 billion, a P/E ratio of 8.82 and a beta of 0.81. Hercules Capital, Inc. has a 52 week low of $13.70 and a 52 week high of $19.62. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.03.

Hercules Capital (NYSE:HTGC – Get Free Report) last issued its earnings results on Thursday, July 30th. The financial services provider reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.02. The business had revenue of $134.41 million during the quarter, compared to analysts’ expectations of $146.71 million. Hercules Capital had a return on equity of 16.01% and a net margin of 67.68%.The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.50 EPS. Analysts forecast that Hercules Capital, Inc. will post 1.95 earnings per share for the current year.

Hercules Capital Increases Dividend The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 18th. Shareholders of record on Tuesday, August 11th were given a dividend of $0.40 per share. This is a positive change from Hercules Capital’s previous quarterly dividend of $0.07. The ex-dividend date of this dividend was Tuesday, August 11th. This represents a $1.60 dividend on an annualized basis and a yield of 9.0%. Hercules Capital’s payout ratio is 79.60%.

Hercules Capital Profile (Free Report)

Hercules Capital, Inc is a specialty finance company organized as a business development company (BDC) that provides tailored debt financing solutions to high‐growth companies. Through its external management structure, Hercules Capital extends senior secured loans, subordinated debt and growth capital designed to support research and development, expansion initiatives and working capital needs. The firm primarily partners with venture capital and private equity sponsors to finance innovative enterprises across various developmental stages.

The company’s investment portfolio is concentrated in technology, life sciences and sustainable and renewable technology sectors, reflecting its focus on industries with strong growth prospects and recurring capital requirements.

Read More Five stocks we like better than Hercules Capital The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now Dropping the Dough: Yum! Brands Strategically Trims the Fat These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern

Receive News & Ratings for Hercules Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hercules Capital and related companies with MarketBeat.com's FREE daily email newsletter.

June 29, 2026 08:00 ET  | Source: 4D Molecular Therapeutics, Inc.

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that it has entered into a strategic credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to $200 million.

“Our strong cash, cash equivalents and marketable securities position, excluding this strategic credit facility, is expected to continue to fund our planned operations into the second half of 2028. Access to this non-dilutive capital further increases our financial strength, providing the Company with strategic and operational flexibility,” said Kristian Humer, Chief Financial Officer of 4DMT. “The credit facility diversifies our capital structure, allowing us to focus on sustaining our execution momentum, growth planning across our innovative gene therapy pipeline and early commercial planning for 4D-150.”

“Hercules Capital is pleased to support 4DMT with a flexible financing solution as the Company advances 4D-150 through Phase 3 development and pre-commercial planning in wet AMD and DME,” said Lake McGuire, Managing Director at Hercules Capital, Inc. “This partnership reflects our commitment to backing innovative genetic medicines with the potential to transform treatment paradigms for patients with serious unmet needs.”

Under the terms of the agreement, 4DMT drew an initial $20 million at closing. An additional $30 million is available, at the Company’s option, through June 15, 2027, with an additional $100 million available upon the Company’s achievement of certain milestones, and the remaining $50 million available subject to final lender approval.

The Company’s cash, cash equivalents and marketable securities were $458 million as of March 31, 2026.

Leerink Partners served as the exclusive financial advisor to 4DMT on the strategic credit facility.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and expressed statements regarding the therapeutic potential and clinical benefits of, as well as the plans, announcements and related timing for, the clinical development of the Company’s product candidates; the Company's expectations regarding financing alternatives and its anticipated cash runway; the availability of, and the Company’s ability to access or draw, additional capital under the credit facility; the achievement of the milestones, conditions or approvals required to access such additional capital; the expected non-dilutive nature and benefits of the credit facility; and the Company’s financial, strategic and operational flexibility. The words "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," “seek,” "predict," “future,” "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled "Risk Factors" in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements, except as may be required by law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Contacts:

Media:

Jenn Gordon
dna Communications
[email protected]

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
[email protected]